29th Napa Pain Conference Posters

Aug 19, 2022 ‐ Aug 21, 2022



Products

The Successful Treatment of Chronic and Refractory Post-Surgical Severe Left Chest and Left Shoulder Pain with Cervical Spinal Cord Stimulation: A Case Report

Preview Available

The Successful Treatment of Chronic and Refractory Post-Surgical Severe Left Chest and Left Shoulder Pain with Cervical Spinal Cord Stimulation: A Case Report

Synopsis

This is the first known published case of its kind on the successful use of cervical spinal cord stimulation for the treatment of chronic and severe pain in the left chest and left shoulder that was of unknown origin despite extensive workup and was refractory to a plethora of treatments including medical management, alternative management, surgery, interventional procedures.


Disclosures

Nothing to Disclose by any Author

Speaker(s):

A self-anchoring injectable helical wire rope structure electrode (Injectrode) enables ease of placement and clear imaging

Preview Available

A self-anchoring injectable helical wire rope structure electrode (Injectrode) enables ease of placement and clear imaging

Synopsis

In order to overcome barriers to adoption of neurostimulation technologies by patients and clinicians, we present here a minimally invasive needle placeable and fully implanted neurostimulator that is suitable for clinical imaging (U/S, X-Ray, MRI). The structural design and placement procedure of the injectable helical wire structure electrode (Injectrode) renders the device self anchoring and deliverable using a minimal number of components. Demonstrated are placements by clinicians on various nerve targets in animal and human models.



Disclosures

  • Stephan Nieuwoudt is employed by and owns equity in Neuronoff, Inc. 
  • Amelia Howe is employed by and owns equity in Neuronoff, Inc. 
  • Johanna Pearson is employed by Neuronoff, Inc. 
  • Emily Szabo is employed by and owns equity in Neuronoff, Inc. 
  • Morgan McGaughey is employed by and owns equity in Neuronoff, Inc. 
  • Derrick Liu is employed by and owns equity in Neuronoff, Inc. 
  • Shaher Ahmad is employed by and owns equity in Neuronoff, Inc. 
  • Kip A. Ludwig is receiving funds from and owns equity in Neuronoff, Inc.
  • Hesham Elsharkawy owns equity in Neuronoff, Inc. 
  • Amol Soin owns equity in Neuronoff, Inc. 
  • Alaa Abd-Elsayed owns equity in Neuronoff, Inc. 
  • Manfred Franke is employed by and owns equity in Neuronoff, Inc. 
  • Andrew J. Shoffstall is receiving funds from and owns equity in Neuronoff, Inc.
  • This project is supported by Neuronoff Inc., NIH 1U18EB029251-01 Grant, and the DARPA EEI program. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense or the National Institutes of Health.

Speaker(s):

Prevalence of headache and its associated factors, Makkah, Saudi Arabia

Preview Available

Prevalence of headache and its associated factors, Makkah, Saudi Arabia

Synopsis

Headache is a common problem worldwide. It can be due to benign or serious conditions. Most of the time the original causes are benign, but it can be disabling that can affect the daily living of individuals and the productivity of community. It is important to know the current prevalence of headaches and the factors that can affect them which can be the leading tool for better assessment and management.


Disclosures

Nothing to disclose by the author.

Speaker(s):
  • Maram Alshareef, Family and Chronic Pain Physician Assistant Professor, Department of Community Medicine and Pilgrims Health, Faculty of Medicine, Umm Al-Qura University

Multimodal Imaging Analysis of Fibromyalgia Syndrome Reveals Structural and Functional Abnormalities in Cortico-Thalamic Loops

Multimodal Imaging Analysis of Fibromyalgia Syndrome Reveals Structural and Functional Abnormalities in Cortico-Thalamic Loops

Synopsis

Here we propose a characterization of Fibromyalgia pathophysiology in gray matter (GM) tissue using a multimodal neuroimaging approach (volumetric, diffusion-weighted, and resting-state functional connectivity).


Disclosures

Nothing to Disclose by any Author

Speaker(s):

Using A Novel Commercial Telehealth Platform To Deliver Pain Management Care And Guided Opioid Tapering Among Post-Operative Head And Neck Cancer Patients

Preview Available

Using A Novel Commercial Telehealth Platform To Deliver Pain Management Care And Guided Opioid Tapering Among Post-Operative Head And Neck Cancer Patients

Head/neck cancer patients experience high pain after surgery, putting them at risk for persistent postoperative opioid use. Using a comprehensive CBT-facilitated telehealth platform seems to be beneficial and approachable for head/neck cancer patients (n = 6) to adequately manage pain after surgery, and ultimately taper 100% off post-surgical opioids. Reduction and cessation of new and persistent opioid use after surgery is possible for head/neck cancer patients.

Speaker(s):
  • Maryam Hussain, PhD, Director of Clinical Research and Development, Lucid Lane

Using an Unconventional Serratus Anterior Plane Block to Treat Post-Herpetic Neuralgia: A Case Report

Preview Available

Using an Unconventional Serratus Anterior Plane Block to Treat Post-Herpetic Neuralgia: A Case Report

Synopsis

A 49-year-old woman with a history of herpes zoster presented with recurrent left lateral flank pain of one year duration. She was diagnosed with post-herpetic neuralgia. After failing conservative therapy and previous intercostal blocks, she underwent a successful left serratus anterior plane block (SAPB) under ultrasound guidance with over 50% maximal pain relief. Although previous studies have shown efficacy of SAPB, our case uses a unique inferior approach beneath the 8th rib in a patient with much longer duration of symptoms. The SAPB is a feasible alternative intervention for patients with recurrent, intractable post-herpetic neuralgic pain.


Disclosures

Nothing to disclose by any author.

Speaker(s):
  • Jason Kessler, Resident Physician, Department of Rehabilitation Medicine at New York University Grossman School of Medicine

Human Transcription Error Assessment within a Simulated Electronic Health Record System

Human Transcription Error Assessment within a Simulated Electronic Health Record System

Synopsis

Medical practices and hospitals have adopted Electronic Health Record (EHR) systems that streamline patient information and relevant clinical data. Access to an EHR system with effective exchange of electronic health information is critical in maintaining data consistency and reliability. Human errors that occur during the transcription of data from one field to another, or from a paper to an electronic record, can negatively impact patient care and reduce efficiency. Human transcription errors can occur as early as the scheduling process, with these errors compounding as more individuals touch and re-transcribe the data. Though previous literature have touched upon error rates, they have not addressed the complexity of patient data involved with scheduling.


Disclosures

Nothing to Disclose by any Author

Speaker(s):

Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment

Preview Available

Exploratory Efficacy of INP104 in Migraine Patients By Prior Treatment

Synopsis

Results suggest that INP104 may be an effective acute treatment option for migraine regardless of prior acute treatment, which includes triptans.


Disclosures

Tanya R. Bilchik has participated in speaker bureaus for AbbVie, Amgen/Allergan, Biohaven Pharmaceuticals, Eli Lilly, Impel Pharmaceuticals, and Teva Pharmaceuticals. Robert Vann, Sutapa Ray, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.

Speaker(s):
  • Sutapa Ray, PhD, Medical Affairs, Impel Pharmaceuticals

Comparison of Non-Narcotic and Narcotic Pain Management Protocols for Knee Arthroscopy: A Retrospective Cohort Study

Preview Available

Comparison of Non-Narcotic and Narcotic Pain Management Protocols for Knee Arthroscopy: A Retrospective Cohort Study

Synopsis

In this study, we compared a non-opioid pharmacologic pain management regimen to a regimen allowing for breakthrough opioids as needed in the postoperative management of patients who underwent elective uncomplicated arthroscopic knee surgery. The non-opioid pain management protocol consisted of oral acetaminophen 650mg q4h x 3 days, gabapentin 300mg TID x 14 days, ketorolac 10mg q6-8h x 5 days, topical lidocaine patch (4%) 1 patch/day x 14 days, and no breakthrough opioids. At two weeks and 6 weeks postoperatively, there were no significant differences in pain scores between the two groups, suggesting non-inferiority of the non-opioid pain management regimen to the traditional approach of postoperative opioid prescription.


Disclosures

Nothing to Disclose by any Author

Speaker(s):

Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications

Preview Available

Exploratory Efficacy of INP104 in Patients Using Concomitant Preventive Migraine Medications

Synopsis

Results suggest that INP104 may be an effective and well-tolerated acute therapy for migraine in patients who are concurrently using preventive therapies.


Disclosures

Jihan Grant participated in an Advisory Board meeting for Satsuma Pharmaceuticals. Robert Vann, Christopher Fitzpatrick, TinaMarie Lieu, Stephen B. Shrewsbury, and Sheena K. Aurora are full-time employees of Impel Pharmaceuticals and are stockholders in Impel Pharmaceuticals. Stephen B. Shrewsbury is an officer of Impel Pharmaceuticals.

Speaker(s):